Skip to content
OpenCapital
Get started

Crinetics Pharmaceuticals CRNX Equity Method Income

Discontinued — last reported Q4 '25

Equity Method Income at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$18.28M-17.5%
Arrowhead Research logo
Arrowhead ResearchARWR
——

Segments

By segment

See full
Reportable Segment$0+100%

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$3.79B+21.9%

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0×0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.

The official record: Crinetics Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's equity method income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Crinetics Pharmaceuticals's equity method income?
Crinetics Pharmaceuticals (CRNX) reported equity method income of $0 in Q4 2025.
What does equity method income mean?
The company's proportional share of net income or loss from unconsolidated affiliates and joint ventures accounted for under the equity method.